share_log

Aclaris Therapeutics (NASDAQ:ACRS) Sees Large Volume Increase

Defense World ·  Jan 29, 2023 03:01

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) shares saw unusually-strong trading volume on Friday . Approximately 758,008 shares traded hands during mid-day trading, an increase of 107% from the previous session's volume of 366,400 shares.The stock last traded at $17.30 and had previously closed at $16.82.

Analysts Set New Price Targets

A number of analysts have weighed in on ACRS shares. Stifel Nicolaus started coverage on Aclaris Therapeutics in a research report on Tuesday, December 13th. They issued a "buy" rating and a $29.00 price target for the company. The Goldman Sachs Group started coverage on Aclaris Therapeutics in a research report on Thursday, December 1st. They issued a "buy" rating and a $25.00 price target for the company. SVB Leerink reaffirmed an "outperform" rating on shares of Aclaris Therapeutics in a research report on Tuesday, November 8th. BTIG Research assumed coverage on Aclaris Therapeutics in a research report on Thursday, October 6th. They issued a "buy" rating and a $32.00 price target for the company. Finally, StockNews.com assumed coverage on Aclaris Therapeutics in a research report on Wednesday, October 12th. They set a "sell" rating for the company. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $28.67.

Get Aclaris Therapeutics alerts:

Aclaris Therapeutics Trading Up 3.9 %

The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -13.55 and a beta of 0.53. The firm has a 50-day moving average of $16.24 and a two-hundred day moving average of $16.06.

Aclaris Therapeutics (NASDAQ:ACRS – Get Rating) last posted its quarterly earnings data on Tuesday, November 8th. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.09. The business had revenue of $19.02 million during the quarter, compared to analysts' expectations of $1.61 million. Aclaris Therapeutics had a negative return on equity of 39.41% and a negative net margin of 349.26%. As a group, equities analysts anticipate that Aclaris Therapeutics, Inc. will post -1.39 EPS for the current year.

Insider Transactions at Aclaris Therapeutics

In other news, insider Joseph Monahan sold 5,000 shares of Aclaris Therapeutics stock in a transaction that occurred on Thursday, December 15th. The stock was sold at an average price of $15.88, for a total transaction of $79,400.00. Following the sale, the insider now owns 96,386 shares of the company's stock, valued at approximately $1,530,609.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Aclaris Therapeutics news, Director Neal Walker sold 25,000 shares of Aclaris Therapeutics stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $15.25, for a total transaction of $381,250.00. Following the sale, the director now owns 1,220,763 shares in the company, valued at $18,616,635.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Joseph Monahan sold 5,000 shares of Aclaris Therapeutics stock in a transaction on Thursday, December 15th. The stock was sold at an average price of $15.88, for a total transaction of $79,400.00. Following the sale, the insider now owns 96,386 shares in the company, valued at approximately $1,530,609.68. The disclosure for this sale can be found here. 6.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Aclaris Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP boosted its stake in Aclaris Therapeutics by 3.4% during the first quarter. Wellington Management Group LLP now owns 5,730,253 shares of the biotechnology company's stock worth $98,789,000 after buying an additional 190,985 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Aclaris Therapeutics by 3.0% during the third quarter. BlackRock Inc. now owns 4,810,298 shares of the biotechnology company's stock valued at $75,714,000 after acquiring an additional 140,382 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Aclaris Therapeutics by 4.2% during the third quarter. Vanguard Group Inc. now owns 2,931,709 shares of the biotechnology company's stock valued at $46,145,000 after acquiring an additional 118,024 shares during the period. Commodore Capital LP lifted its holdings in shares of Aclaris Therapeutics by 4.1% during the second quarter. Commodore Capital LP now owns 2,410,622 shares of the biotechnology company's stock valued at $33,652,000 after acquiring an additional 95,974 shares during the period. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Aclaris Therapeutics by 6.9% during the third quarter. Point72 Asset Management L.P. now owns 1,853,251 shares of the biotechnology company's stock valued at $29,170,000 after acquiring an additional 119,351 shares during the period. Institutional investors and hedge funds own 95.33% of the company's stock.

About Aclaris Therapeutics

(Get Rating)

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.

See Also

  • Get a free copy of the StockNews.com research report on Aclaris Therapeutics (ACRS)
  • MarketBeat Week in Review – 1/23- 1/27
  • Why Lucid Spiked Nearly 100% In One Day
  • Ride These Railroad Stocks for Growth and Income
  • ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
  • KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment